PER-001-20尚未招募未知
AN OPEN-LABEL, MULTICENTER EXTENSION AND LONG-TERM OBSERVATIONAL STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN-LA ROCHE LTDSPONSORED ATEZOLIZUMAB STUDY
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients must meet the following criteria for study entry: • Signed extension study Informed Consent Form • Discontinuation of atezolizumab-based therapy in parent study and in survival follow up at the time of parent study closure. Criteria mentioned in the section: 2. Specific criteria for patients who do not continue treatment in the extension study and/or receive commercially available atezolizumab (Tecentriq) outside this extension study and continue safety and survival follow-up only in the extension study.
排除标准
- •Patients who meet the following criteria will be excluded from study entry: • Discontinuation of comparator in parent study and in survival follow-up at the time of parent study closure.
- •Criteria mentioned in the section: 2. Specific criteria for patients who do not continue treatment in the extension study and/or receive commercially available Tecentriq outside this extension study and continue safety and survival follow-up only in the extension study.
研究者
相似试验
进行中（未招募）
1 期
An Extension and Long-Term Observational Study in Patients Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab StudyEUCTR2016-005189-75-SIF. Hoffmann-La Roche Ltd385
进行中（未招募）
1 期
An Extension and Long-Term Observational Study in Patients Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab StudyCancer(Future parent protocols may include other cancer that are not included in this section)MedDRA version: 21.0Level: LLTClassification code 10046721Term: Urothelial carcinoma bladder stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10023400Term: Kidney cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-005189-75-LVF. Hoffmann-La Roche Ltd556
进行中（未招募）
1 期
An Extension and Long-Term Observational Study in Patients Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab StudyEUCTR2016-005189-75-DEF. Hoffmann-La Roche Ltd385
进行中（未招募）
1 期
An Extension and Long-Term Observational Study in Patients Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab StudyEUCTR2016-005189-75-BEF. Hoffmann-La Roche Ltd385
进行中（未招募）
1 期
An Extension and Long-Term Observational Study in Patients Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab StudyCancer(Future parent protocols may include other cancer that are not included in this section)MedDRA version: 21.0Level: LLTClassification code 10046721Term: Urothelial carcinoma bladder stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10023400Term: Kidney cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-005189-75-PTF. Hoffmann-La Roche Ltd385